Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Journal of Central South University(Medical Sciences) ; (12): 114-122, 2023.
Artículo en Inglés | WPRIM | ID: wpr-971376

RESUMEN

OBJECTIVES@#The use of anticholinergic drugs in the elderly may lead to negative events such as falls, delirium, urinary retention and cognitive decline, and the higher the number of anticholinergic drugs use, the more such negative events occur. This study aims to analyze the risk factors associated with the prescription of total anticholinergic drugs in elderly outpatients and evaluate the rationality of anticholinergic drugs, and to provide a reference for reducing the adverse effects of anticholinergic drugs.@*METHODS@#A list of drugs with anticholinergic activity based on the Beers criteria was established. The basic information (such as age and gender), clinical diagnosis, and medications of elderly outpatient were extracted from hospital electronic medical records, and the Anticholinergic Cognitive Burden (ACB) Scale was used to calculate the anticholinergic burden for each patient. Logistic regression analysis was used to identify the potential risk factors for the occurrence of problems such as multiple medication and insomnia.@*RESULTS@#A total of 1 840 prescriptions for elderly patients were reviewed. Of these patients, ACB score was more than or equal to 1 in 648 (35.22%) patients. Number of prescription medication (95% CI: 1.221 to 1.336) and insomnia (95% CI: 3.538 to 6.089) were independent factors affecting ACB scores (both P<0.01). Medications for patients of ACB scores were most commonly treated with the central nervous system drugs (such as alprazolam and eszopiclone) and for the cardiovascular system drugs (such as metoprolol and nifedipine).@*CONCLUSIONS@#There is a high rate of ACB drugs use in geriatric patients, and the clinical focus should be on multiple medication prescriptions, especially on the central nervous system drugs (such as alprazolam and eszopiclone) and cardiovascular system drugs (such as metoprolol and nifedipine). The prescription review should be emphasized to reduce adverse reactions to anticholinergic drugs in elderly patients.


Asunto(s)
Humanos , Anciano , Antagonistas Colinérgicos/efectos adversos , Pacientes Ambulatorios , Metoprolol , Alprazolam , Eszopiclona , Nifedipino , Trastornos del Inicio y del Mantenimiento del Sueño , Factores de Riesgo
2.
Clinics ; 71(1): 5-9, Jan. 2016. tab
Artículo en Inglés | LILACS | ID: lil-771945

RESUMEN

OBJECTIVE: To determine the therapeutic effects of two selective GABA-A agonists, zopiclone and eszopiclone, in the treatment of insomnia. METHODS: This study comprised a phase III, single-center, randomized, double-blind, double-dummy, parallel-group, non-inferiority trial. Patients were randomized to receive zopiclone 7.5 mg or eszopiclone 3 mg, both orally, for four weeks. In total, 199 patients were evaluated during two visits and then followed for at least six weeks. The primary endpoint was the Insomnia Severity Index after four weeks of treatment. Secondary endpoints were obtained through polysomnography data, including total sleep time, sleep latency and sleep efficiency. The frequency of adverse events was also analyzed. ClinicalTrials.gov: NCT01100164. RESULTS: The primary efficacy analysis demonstrated the non-inferiority of eszopiclone over zopiclone. Analysis of objective parameters assessed by polysomnography showed that eszopiclone increased total sleep time and also improved sleep efficiency. The safety profile of both study treatments was similar and the most common events reported in both groups were dysgeusia, headache, dizziness, irritability and nausea. Adverse events were observed in 223 patients, 109 (85.2%) in the eszopiclone group and 114 (87.7%) in the zopiclone group. CONCLUSION: Based on the Insomnia Severity Index at the end of four weeks of treatment, eszopiclone demonstrated efficacy comparable to that of zopiclone in the treatment of insomnia, increasing total sleep time as well as sleep efficiency according to polysomnography.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Compuestos de Azabiciclo/uso terapéutico , Eszopiclona/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Piperazinas/uso terapéutico , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Compuestos de Azabiciclo/efectos adversos , Método Doble Ciego , Disgeusia/inducido químicamente , Eszopiclona/efectos adversos , Cefalea/inducido químicamente , Hipnóticos y Sedantes/efectos adversos , Polisomnografía , Piperazinas/efectos adversos , Resultado del Tratamiento
3.
Journal of Forensic Medicine ; (6): 367-373, 2010.
Artículo en Chino | WPRIM | ID: wpr-983598

RESUMEN

In forensic toxicology analysis, various types of biological samples have their own special characteristics and scope of applications. In this article, the physiological structure of nails, methods for collecting and pre-processing samples, and for analyzing some poisons and drugs in the nails are reviewed with details. This paper introduces the influence factors of drug abuse of the nails. The prospects of its further applications are concluded based on the research results. Nails, as an unconventional bio-sample without general application, show great potential and advantages in forensic toxicology.


Asunto(s)
Humanos , Alprazolam/análisis , Compuestos de Azabiciclo/análisis , Cromatografía Líquida de Alta Presión/métodos , Cocaína/análisis , Diazepam/análisis , Eszopiclona , Toxicología Forense/métodos , Cromatografía de Gases y Espectrometría de Masas/métodos , Cabello/química , Drogas Ilícitas/análisis , Uñas/fisiología , Piperazinas/análisis , Manejo de Especímenes/métodos , Detección de Abuso de Sustancias/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA